ScoreWhy is Keros Therapeutics, Inc. ?
1
With a growth in Net Sales of 49002.7%, the company declared Very Positive results in Jun 25
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 55.04 MM
- NET SALES(HY) Higher at USD 229.41 MM
- NET PROFIT(HY) Higher at USD 117.75 MM
2
With ROE of 0.58%, it has a attractive valuation with a 0.84 Price to Book Value
- Over the past year, while the stock has generated a return of -69.39%, its profits have risen by 102.6% ; the PEG ratio of the company is 1.4
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Keros Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Keros Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Keros Therapeutics, Inc.
-67.45%
-0.72
90.02%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
115.58%
EBIT Growth (5y)
15.00%
EBIT to Interest (avg)
-81.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.08
Tax Ratio
71.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.14%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
145
Industry P/E
Price to Book Value
0.84
EV to EBIT
10.43
EV to EBITDA
11.94
EV to Capital Employed
-10.31
EV to Sales
-0.50
PEG Ratio
1.42
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
0.58%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 55.04 MM
NET SALES(HY)
Higher at USD 229.41 MM
NET PROFIT(HY)
Higher at USD 117.75 MM
ROCE(HY)
Highest at 3.33%
DEBTORS TURNOVER RATIO(HY)
Highest at 24.4 times
RAW MATERIAL COST(Y)
Fallen by -113.32% (YoY
CASH AND EQV(HY)
Highest at USD 1,410.76 MM
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Keros Therapeutics, Inc.
Net Sales
At USD 229.41 MM has Grown at 191,078.33%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Profit
At USD 117.75 MM has Grown at 233.25%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Higher at USD 229.41 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Net Profit
Higher at USD 117.75 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 24.4 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Operating Cash Flow
Highest at USD 55.04 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Cash and Eqv
Highest at USD 1,410.76 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by -113.32% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
